Social Isolation and Aging in Schizophrenia
NCT07419321
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Individuals diagnosed with schizophrenia and related psychotic disorders (SZ) exhibit a markedly elevated risk of premature mortality, with a 10-20-year shorter lifespan relative to the general population. Increased mortality rates in SZ are largely attributable to the early manifestation of medical conditions that normally occur later in life, a process known as 'accelerated aging'. While unhealthy lifestyle behaviors, such as smoking and unhealthy diet, account, in part, for accelerated aging in SZ, the excess of physical comorbidities cannot be solely attributed to these factors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia and Related Disorders
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 40 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Last updated on ClinicalTrials.gov
- February 19, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Olin Neuropsychiatry Research Center, Hartfort · Hartford, CT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.